
Sight Sciences (SGHT) Stock Forecast & Price Target
Sight Sciences (SGHT) Analyst Ratings
Bulls say
Sight Sciences is supported by two distinct growth engines: the OMNI/SION glaucoma franchise and TearCare in dry eye, both of which showed strong Q3 momentum with total revenue of $24.9 million, up 25.2% year over year, and gross margin of 85.9%. The interventional glaucoma business grew 6.7% year over year, while dry eye surged 45% sequentially to $3.9 million, alongside rising unit volumes and active customers, indicating improving adoption and reimbursement traction. Management also lifted FY26 revenue guidance to $92 million-$93 million, and the combination of revenue growth, improving operating leverage, large addressable markets, and the $55.4 million Alcon judgment supports a constructive fundamental view.
Bears say
Sight Sciences is under pressure from persistent operating losses, with negative operating cash flow of ($12.7M) in 1H26 versus ($19.1M) in 1H25, a $38.4 million net loss in FY2025, and a $402.1 million accumulated deficit as of June 30, 2026, while management has offered no target date for cash-flow breakeven. Its balance sheet and financing profile add risk, as $79.8 million of cash is offset by a $40.0 million term loan bearing a 10.35% floor, with amortization starting February 1, 2027, plus restrictive covenants and secured claims on substantially all assets. Fundamentally, revenue concentration, weak growth visibility, reimbursement uncertainty, competitive pressure, tariff-sensitive supply chain exposure, and unresolved legal and patent issues make the outlook fragile despite OMNI’s EU MDR approval in December 2023.
This aggregate rating is based on analysts' research of Sight Sciences and is not a guaranteed prediction by Public.com or investment advice.
Sight Sciences (SGHT) Analyst Forecast & Price Prediction
Start investing in Sight Sciences (SGHT)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Sight Sciences (SGHT) Forecast
Sight Sciences (SGHT) Analyst Forecast & Price Prediction
Start investing in Sight Sciences (SGHT)
Order type
Buy in
Order amount
Est. shares
0 shares